Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel epigenetic biomarker for detecting bladder cancer and method thereof

A technology for biomarkers and bladder cancer, applied in biochemical equipment and methods, microbe determination/testing, DNA/RNA fragments, etc., can solve problems such as not good methods

Active Publication Date: 2015-04-15
GUZIP BIOMARKERS CORP
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the nature of the interaction between genetics and the environment, the degree of methylation of tumor suppressor genes varies with different genes and different ethnic groups, and different diseases also have different methylator phenotypes; however, in bladder cancer What specific genes will be methylated, and how many genes are needed to meet the needs of clinical applications, these issues still need to be confirmed in the future
[0006] The above-mentioned existing bladder cancer screening methods still have many deficiencies and are indeed not a good method, but urgently need to be improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel epigenetic biomarker for detecting bladder cancer and method thereof
  • Novel epigenetic biomarker for detecting bladder cancer and method thereof
  • Novel epigenetic biomarker for detecting bladder cancer and method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] The methylation array identified new methylation target genes in bladder cancer patient samples: we used the illumina infinium27K methylation array to select a higher methylation ratio score (beta value > 0.5 for methylation) and compare it to normal bladder urothelial epithelium Cells and CpG island methylated regions of seven human bladder cancer samples, in which the ZNF671 target gene showed its promoter sequence was highly methylated in bladder cancer samples and was therefore selected for further analysis.

Embodiment 2

[0058] ZNF671 gene methylation in urine can be used as a detection tool:

[0059] To assess the feasibility of using DNA methylation as a marker of cancer detection and recurrence monitoring, methylation was detected using the more sensitive quantitative MSP (QMSP) method in urine from 28 bladder cancer patients and 19 non-cancer patients state( figure 1 ). The average number of ZNF671 in normal samples was 1.69, and the average number in cancer samples was 19.24. Compared with the non-cancer control group, the ZNF671 gene had a higher degree of methylation in cancer samples (P<0.001). The sensitivity and specificity of ZNF671 gene in the detection of cancer were 42.3% and 100%, respectively.

Embodiment 3

[0061] Other target gene methylation in urine can be used as a detection tool:

[0062] We also used qMSP to assess the methylation status of target genes in the urine of bladder cancer patients. The target genes are: PTPRR, SOX1, PAX1, ZNF582 ( figure 2 ); AJAP1, SOX17, EDN3, ST6GAL2 ( image 3 ); ZNF614, PTGDR, SYT9, SOX8 ( Figure 4 ); HS3ST2, POU4F3, ADRA1D, MAGI2 ( Figure 5 ); EPO, NEFH, POU4F2 ( Figure 6 ); STC2, THRB ( Figure 7 ). Table 4 shows the average number of target gene normal and bladder cancer samples in each group. The results showed that compared with normal non-cancer urine samples, these target genes had a higher degree of methylation in the urine samples of bladder cancer patients.

[0063] Table 4. The degree of methylation of each target gene

[0064]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A novel epigenetic biomarker for detecting bladder cancer and a method thereof. The method comprises following steps: (1) providing a to-be-detected specimen; (2) detecting a CpG sequence methylation status of at least one targeted gene in genome DNA of the to-be-detected specimen, wherein the targeted gene is selected from at least one of the group consisting of ZNF671, PTPRR, SOX1, PAX1, ZNF582, AJAP1, SOX17, EDN3, ST6GAL2, ZNF614, PTGDR, SYT9, SOX8, HS3ST2, POU4F3, ADRA1D, MAGI2, EPO, NEFH, POU4F2, STC2 and THRB; and determining whether the specimen is suffered from cancer or precancerous lesions or not according to whether the methylation status of the targeted gene exists or not, or employing the determination of the existence of the methylation status of the targeted gene as treatment prognosis. The invention also discloses a novel epigenetic biomarker for detecting the bladder cancer, wherein the biomarker comprises a methylated CpG locus of the target gene. The methylated CpG locus can be detected in urine.

Description

technical field [0001] The present invention relates to a novel epigenetic biomarker for detecting bladder cancer and its method, in particular to a method for screening bladder cancer using methylated DNA as a biomarker. Background technique [0002] Bladder cancer is the sixth most common cancer in the world and has a particularly high incidence in southwestern Taiwan. About 90% of bladder cancer is urothelial carcinoma (UC), also known as transitional cell carcinoma (TCC), about 8% of bladder cancer is squamous cell carcinoma, and about 2% is adenocarcinoma . Although the mortality rate of bladder cancer patients is low, long-term follow-up and repeated cystoscopy are necessary because bladder cancer is a high-recurrence tumor. For a detailed bladder exam, to detect abnormalities in the bladder, a cystoscope is used directly through the patient's urethra, and most patients undergo these invasive procedures. [0003] Gene deletions (genomic deletions) are considered to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6886C12Q2600/118C12Q2600/154
Inventor 陈永恩陈丕哲徐政达叶佳铭赖鸿政张德卿沈正煌
Owner GUZIP BIOMARKERS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com